Celularity Files 10-K, Regains Nasdaq Compliance, Highlights Strategic Shift
CELU is trading near its 52-week low of $0.931 (9.6% above the low) on elevated volume (3.1× avg).
Summary
Celularity Inc. has filed its Annual Report on Form 10-K for fiscal year 2025, successfully regaining compliance with Nasdaq's listing requirements for timely financial reporting. This resolves a previously disclosed non-compliance notification received on April 16, 2026, which posed a delisting threat. The company also highlighted its ongoing strategic transformation, which includes the out-licensing of its biomaterials portfolio, personnel realignment, and a significant $13 million reduction in liabilities. While the debt reduction was previously announced in an April 21st 8-K, the filing of the 10-K and the confirmed resolution of the Nasdaq compliance issue are critical for maintaining investor confidence and market access for this micro-cap company. Traders will now look for continued execution on the company's refocused longevity and cell therapy strategy.
At the time of this announcement, CELU was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.6M. The 52-week trading range was $0.93 to $4.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.